Episode 53 - The Collective Lie in Ketamine Therapy (Part 2): MSKIT Protocol and the Future of Ketamine Therapy
Charles Miller details his evidence-based MSKIT protocol, explains optimal timing for ketamine therapy, and shares his vision for bringing scientific rigor to the ketamine therapy field.
In Part 2 of our conversation with Charles Miller from Scenic City Neurotherapy, we get into the practical side of his controversial "collective lie" thesis from Part 1.
Charles walks through his MSKIT (Minimally Stimulated Ketamine Infusion Therapy) approach, explaining when he believes therapeutic integration should actually happen: weeks after treatment during the neuroplasticity window, not during altered states. He addresses how he manages patient expectations around epiphanies and insights, arguing these are retrospective brain noise rather than therapeutic mechanisms.
You'll hear Charles use memorable analogies—from cheese obsessions to rollercoaster highs—to explain why he believes the psychedelic experience itself isn't doing the heavy lifting. He makes the case that ketamine is upgrading synaptic function, not providing mystical cures, and that the real work happens when patients are sober and doing therapy afterward.
Through detailed audio sidebars, we explore the crucial relationship between BDNF and sleep (and why post-treatment rest matters more than most clinics acknowledge), and examine the metabolite pathway that creates ketamine's addiction potential.
Charles also shares his vision for the future of ketamine therapy, advocating for greater scientific rigor and proper medical oversight while critiquing the growing trend of unqualified providers administering ketamine.
If you're questioning whether the approaches many of us have been using actually serve our patients best, this conversation will give you a lot to think about.
What You'll Learn in This Episode:
Patient education strategies - How to remove performance pressure by explaining "you can't make this work better or worse" and framing treatment as physiology, not psychology
Managing epiphanies and insights - Charles's perspective on why experiences are retrospective brain noise rather than therapeutic mechanisms, and how to validate without overemphasizing
BDNF and sleep optimization - The critical relationship between post-treatment sleep quality and neuroplasticity consolidation that many clinics overlook
Ketamine's addiction pathway - Understanding the hydroxynorketamine metabolite mechanism and why "more is not better" with dosing protocols
Pain protocol applications - How he incorporates NAD, lidocaine, magnesium, and anti-inflammatories for comprehensive chronic pain treatment
Future field vision - Charles's call for greater scientific rigor, proper medical oversight, and evidence-based protocols over speculative experiential approaches.
Key Takeaways:
Therapeutic integration may be more effective up to weeks after ketamine treatment when the neuroplasticity window is active, rather than during altered states when processing capacity is diminished
Patient education could focus on removing performance pressure by explaining ketamine as physiological process rather than psychological work, helping patients understand "you can't mess this up"
Ketamine experiences might be retrospective rather than revelatory, reflecting existing knowledge without noise rather than generating new insights, which suggests focusing on post-treatment integration work
Sleep quality in days following ketamine treatment could significantly impact neuroplasticity consolidation, as BDNF release during rest helps lock in synaptic changes initiated by treatment
Ketamine's addiction potential may stem from the hydroxynorketamine metabolite binding to opioid receptors at high doses, supporting protocols that emphasize "more is not better" dosing approaches
Mental health symptoms might represent accurate emotional responses to synaptic dysfunction rather than diseases themselves, with ketamine enhancing processing speed and accuracy rather than changing brain content
Providers could benefit from understanding ketamine's "dirty drug" pharmacology, including sodium channel blocking effects that contribute to dissociation and can be addressed with targeted adjuncts like lidocaine
Listen to the episode on Apple Podcasts, Spotify, Overcast, or on your favorite podcast platform. Watch the discussion on YouTube here.
Episode 53 show notes:
00:00:00 - Teaser: This Is Not Magic, This Is Science
00:00:17 - Introduction and Part 2 Setup
00:01:54 - When Therapy Should Actually Happen: Physical Therapy Doesn't Occur During Surgery
00:02:48 - Optimal Timing for Therapeutic Integration: The Weeks That Follow Treatment
00:05:31 - The Science Behind Post-Treatment Rest: BDNF Release and Sleep
00:07:25 - Audio Sidebar: BDNF and Sleep Connection
00:09:29 - Managing Patient Epiphanies: The Cheese Story and Brain Noise
00:13:30 - Mental Health as Synaptic Processing Speed
00:16:45 - Why Experience-Driven Treatment Would Require Daily Ketamine
00:18:04 - MSKIT Protocol: Minimally Stimulated Ketamine Infusion Therapy
00:22:12 - Minimally Stimulating Environment: Binaural Beats and Brain Noise
00:25:30 - Pain Protocols and the "Dirty Drug" Concept
00:26:57 - Audio Sidebar: Ketamine's Metabolite Addiction Pathway
00:30:31 - Future Vision: Greater Rigor and Medical Oversight
00:34:56 - Rapid Fire Personal Questions
00:42:55 - Final Thoughts and Episode Wrap-up
Thanks for Listening
Professional Education Disclaimer: This content is intended exclusively for licensed healthcare professionals and should not be used by patients for self-treatment or self-education. The information presented reflects individual provider experiences and should not replace clinical judgment, professional training, or comprehensive research. Healthcare providers must conduct their own due diligence, consult current literature, and evaluate treatment approaches within their specific practice context and regulatory environment. This educational content does not constitute medical advice for specific patients or clinical situations - treatment decisions should always be based on individual patient assessment and adherence to professional medical standards.
Frequently Asked Questions
What's the optimal timing for therapy integration after ketamine treatment?
Charles recommends waiting weeks after the treatment series for intensive therapy work. He suggests completing a six-infusion series over 2-3 weeks, taking a two-week break, then evaluating at week five before pairing with a therapist for integration work. This timing allows the neuroplasticity window to be fully active when patients are sober and can engage in meaningful therapeutic processing, rather than attempting therapy during altered states when cognitive processing is impaired.
How does the MSKIT protocol differ from standard ketamine therapy?
MSKIT (Minimally Stimulated Ketamine Infusion Therapy) focuses on IV administration exclusively, maintains steady-state blood levels for 40+ minutes minimum, uses the research-supported 0.6-1.2 mg/kg dosing range, and incorporates minimally stimulating environments with binaural beats or understimulating audio. The protocol emphasizes patient education about physiology rather than psychology, removing performance pressure by explaining that patients cannot influence treatment effectiveness through effort or intention.
How should providers handle patients who have profound experiences during treatment?
Based on Charles's perspective, he validates the positive experience while explaining his view that it's retrospective brain noise rather than the therapeutic mechanism. He describes epiphanies as the brain reflecting on existing knowledge without its usual noise, rather than generating new insights. In his explanation, while beautiful experiences can provide positive mindset benefits (he uses the analogy of a good roller coaster ride), the actual therapeutic change occurs through neuroplasticity weeks later, not through the experiential content itself.
Why does Charles emphasize sleep quality after ketamine treatments?
Sleep provides the physiological conditions where BDNF can effectively consolidate neuroplastic changes initiated by ketamine. During daily activity, synapses are strengthened and pruned, but sleep allows the brain to "plug back in" areas and stabilize changes. Since ketamine triggers rapid BDNF release, subsequent sleep quality directly impacts how effectively those neuroplastic opportunities get locked in. Poor sleep may blunt long-term therapeutic gains from the treatment.
What makes ketamine addiction different from traditional opioid addiction?
Ketamine itself isn't an opioid, but its metabolite hydroxynorketamine can bind to opioid receptors and create opioid-style physical dependence at high doses or with chronic use. This typically becomes problematic with recreational high-dose patterns rather than supervised clinical protocols. At therapeutic doses with appropriate spacing, this metabolite doesn't accumulate sufficiently to engage opioid-receptor-mediated dependence, which is why clinical oversight and proper dosing protocols matter for safety.
How can providers implement more evidence-based ketamine protocols?
Providers might consider focusing on administration route optimization (IV over other routes), maintaining proper infusion duration for steady-state levels, using research-supported dosing ranges, and emphasizing post-treatment care including sleep hygiene and lifestyle factors. Charles advocates for collaboration between medical specialties, ensuring airway management capability is available, and building protocols around neuroplasticity science rather than experiential speculation. For more information about Charles's MSKIT protocol and approach, visit www.sceniccityneurotherapy.com.
Connect with Charles Miller & Scenic City Neurotherapy:
Links Relevant To The Episode:
Charles Miller's Research:
Ketamine Pharmacology & Metabolite Research: